These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19789417)
41. Comparison of neointimal coverage and extra-stent lumen between sirolimus and everolimus-eluting stent using optical coherence tomography. Oda T; Okamura T; Yamada J; Miyagi N; Uehara H; Nao T; Tateishi H; Maeda T; Nakamura T; Shiraishi K; Nakashima T; Nishimura S; Miura T; Matsuzaki M; Yano M Heart Vessels; 2016 Apr; 31(4):449-56. PubMed ID: 25614415 [TBL] [Abstract][Full Text] [Related]
42. Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy. Yamamoto M; Okamatsu K; Inami S; Takano M; Yokoyama S; Ohba T; Ibuki C; Hata N; Seino Y; Mizuno K Am Heart J; 2009 Jul; 158(1):99-104. PubMed ID: 19540398 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study. Lee SW; Lam SC; Tam FC; Chan KK; Shea CP; Kong SL; Wong AY; Yung A; Zhang LW; Tse HF; Wu KK; Chan R; Haude M; Mehran R; Mintz GS; Maehara A Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418609 [TBL] [Abstract][Full Text] [Related]
44. Optical coherence tomography evaluation of late strut coverage patterns between first-generation drug-eluting stents and everolimus-eluting stent. Toledano Delgado FJ; Alvarez-Ossorio MP; de Lezo Cruz-Conde JS; Bellido FM; Romero Moreno MÁ; Fernández-Aceytuno AM; de Lezo Herrerosde Tejada JS; Pineda SO; Saint-Gerons JM; Pavlovic D Catheter Cardiovasc Interv; 2014 Nov; 84(5):720-6. PubMed ID: 24174291 [TBL] [Abstract][Full Text] [Related]
45. [Evaluation of neointimal coverage and thrombosis at 3 months and 2 years post sirolimus-eluting stent implantation by optical coherence tomography]. Xie Y; He SH; Gu X; Xu RX; Masamichi T; Kyoichi M Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Feb; 38(2):116-20. PubMed ID: 20398555 [TBL] [Abstract][Full Text] [Related]
46. Accuracy of optical coherence tomography in the evaluation of neointimal coverage after stent implantation. Murata A; Wallace-Bradley D; Tellez A; Alviar C; Aboodi M; Sheehy A; Coleman L; Perkins L; Nakazawa G; Mintz G; Kaluza GL; Virmani R; Granada JF JACC Cardiovasc Imaging; 2010 Jan; 3(1):76-84. PubMed ID: 20129535 [TBL] [Abstract][Full Text] [Related]
47. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Takano M; Inami S; Jang IK; Yamamoto M; Murakami D; Seimiya K; Ohba T; Mizuno K Am J Cardiol; 2007 Apr; 99(8):1033-8. PubMed ID: 17437723 [TBL] [Abstract][Full Text] [Related]
48. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography. Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303 [TBL] [Abstract][Full Text] [Related]
49. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial. Windecker S; Haude M; Neumann FJ; Stangl K; Witzenbichler B; Slagboom T; Sabaté M; Goicolea J; Barragan P; Cook S; Piot C; Richardt G; Merkely B; Schneider H; Bilger J; Erne P; Waksman R; Zaugg S; Jüni P; Lefèvre T Circ Cardiovasc Interv; 2015 Feb; 8(2):e001441. PubMed ID: 25634905 [TBL] [Abstract][Full Text] [Related]
50. Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study. Nakamura D; Lee Y; Yoshimura T; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y; Hara M; Sakata Y; Hamasaki T; Nishino M EuroIntervention; 2014 Dec; 10(8):924-33. PubMed ID: 24602858 [TBL] [Abstract][Full Text] [Related]
51. Optical coherence tomography findings in lesions after sirolimus-eluting stent implantation with peri-stent contrast staining. Tada T; Kadota K; Hosogi S; Kubo S; Ozaki M; Yoshino M; Miyake K; Eguchi H; Ohashi N; Hayakawa Y; Saito N; Otsuru S; Hasegawa D; Shigemoto Y; Habara S; Imai M; Tanaka H; Fuku Y; Oka N; Kato H; Yamamoto H; Fujii S; Goto T; Mitsudo K Circ Cardiovasc Interv; 2012 Oct; 5(5):649-56. PubMed ID: 23011265 [TBL] [Abstract][Full Text] [Related]
52. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. Di Lorenzo E; De Luca G; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G JACC Cardiovasc Interv; 2009 Jun; 2(6):515-23. PubMed ID: 19539255 [TBL] [Abstract][Full Text] [Related]
53. Histological validation of frequency domain optical coherence tomography for the evaluation of neointimal formation after a novel polymer-free sirolimus-eluting stent implantation. Fu Q; Hu H; Chen W; Tan Z; Li L; Wang D; Chen B Int J Clin Exp Pathol; 2015; 8(9):11068-75. PubMed ID: 26617825 [TBL] [Abstract][Full Text] [Related]